皮炎患者筛查系列之外补充斑贴试验的重要性:北美接触性皮炎小组经验
该研究基于北美接触性皮炎小组(NACDG)2001年1月1日至2018年12月31日多个中心的数据,回顾性横断面分析43 417例接受65至70种变应原筛查系列斑贴试验的皮炎患者。结果显示9507例(21.9%)对一种或以上补充(非筛查)变应原或物质存在目前相关反应,其中2447例(25.7%)对NACDG筛查变应原无目前相关反应。作者认为,除筛查系列外,增加专科变应原及个人或工作用品对成功诊断和管理过敏性接触性皮炎至关重要。
要点
- 43 417例皮炎患者中21.9%对补充变应原/物质有目前相关反应。
- 补充阳性者中25.7%对NACDG筛查变应原无目前相关反应。
- 作者认为增加专科及个人或工作用品变应原对诊断管理重要。
核心结论
- 21.9%接受65至70种变应原筛查系列斑贴试验的患者对至少一种补充变应原/物质有相关反应,其中四分之一仅对补充变应原/物质反应;作者认为增加专科变应原及个人或工作用品对成功诊断和管理过敏性接触性皮炎至关重要。
研究设计与样本
- 17年回顾性横断面分析(2001年1月1日至2018年12月31日),纳入北美多个中心NACDG数据,共43 417例皮炎患者以标准化方式接受65至70种变应原的NACDG筛查系列及按临床指征补充变应原斑贴试验。
主要发现
- 43 417例中9507例(21.9%)对一种或以上补充变应原或物质有目前相关反应;其中女性6608例(69.5%),平均(SD)年龄47.2(0.54)岁。
- 与补充阴性患者相比,补充阳性患者为男性的可能性显著更低(OR 0.90;95%CI 0.85-0.94;P<.001),和/或患特应性皮炎的可能性显著更低(OR 0.89;95%CI 0.84-0.93;P<.001)。
- 9499例补充阳性患者常见主要皮炎部位包括面部2856例(30.1%)、手部2029例(21.4%)和散在/泛发分布1645例(17.3%)。
- 9235例中补充变应原常见来源为个人护理产品4746例(51.4%)和衣物/穿着用品1674例(18.1%)。
- 9362例有数据者中1580例(16.9%)补充变应原/物质与职业相关;在已识别职业者中25.1%(384/1529)为精密生产、工艺或维修工人;9507例补充阳性者中2447例(25.7%)对NACDG筛查变应原无目前相关反应。
关键数值与推荐
- 补充阳性定义为对一种或以上补充(非筛查)变应原或物质存在目前相关反应。
- 补充阳性患者为男性的OR为0.90(95%CI 0.85-0.94;P<.001),患特应性皮炎的OR为0.89(95%CI 0.84-0.93;P<.001),均与补充阴性患者比较。
临床怎么用
- 作者认为,在筛查系列基础上增加专科变应原及个人或工作用品对过敏性接触性皮炎的成功诊断和管理至关重要。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Patch test screening series for patients with dermatitis are limited and may miss clinically relevant contact allergens. OBJECTIVE: To characterize individuals with dermatitis who showed clinically relevant patch test findings to supplemental (nonscreening) allergens or substances. DESIGN, SETTING, AND PARTICIPANTS: A 17-year, retrospective cross-sectional analysis (January 1, 2001, to December 31, 2018) of North American Contact Dermatitis Group (NACDG) data from multiple centers in North America was conducted. A total of 43 417 patients with dermatitis underwent patch testing to the NACDG screening series in a standardized manner with 65 to 70 allergens and supplemental allergens as clinically indicated. Patients with 1 or more clinically relevant reactions to a supplemental (nonscreening) allergen/substance were analyzed between November 18, 2020, and March 12, 2021. MAIN OUTCOMES AND MEASURES: The main outcomes were to assess the number of patients with clinically relevant reactions to supplemental (nonscreening) allergens and compare characteristics (including demographic characteristics and occupations) between patients with a clinically relevant patch test reaction to 1 or more supplemental allergens or substances (supplement-positive) and those without a reaction (supplement-negative) using odds ratios (ORs) and 95% CIs. Secondary outcomes included sources of allergic contact dermatitis and, for occupationally related cases, specific occupations and industries. RESULTS: Of 43 417 patients included in the study who underwent patch testing to the NACDG screening series (65-70 allergens), 9507 individuals (21.9%) had currently relevant reactions to 1 or more supplemental allergens or substances. Of these, 6608 were women (69.5%) and the mean (SD) age was 47.2 (0.54) years. Compared with patients who had supplement-negative results, patients with supplement-positive findings were significantly less likely to be male (OR, 0.90; 95% CI, 0.85-0.94; P < .001) and/or have atopic dermatitis (OR, 0.89; 95% CI, 0.84-0.93; P < .001). Common primary sites of dermatitis in 9499 patients with supplement-positive findings included the face (2856 [30.1%]), hands (2029 [21.4%]), and scattered/generalized distribution (1645 [17.3%]). Frequent sources of supplemental allergens in 9235 patients included personal care products (4746 [51.4%]) and clothing/wearing apparel (1674 [18.1%]). Of 9362 patients with available data, supplemental allergens/substances were occupationally related in 1580 (16.9%); of those with identified occupations, 25.1% (384 of 1529) were precision production, craft, or repair workers. Of 9507 patients with supplement-positive findings, 2447 (25.7%) had no currently relevant reactions to NACDG screening allergens. CONCLUSIONS AND RELEVANCE: This cross-sectional study found that 21.9% of patients who underwent patch testing to an allergen screening series of 65 to 70 allergens had at least 1 relevant reaction to supplemental allergens/substances. Of these, one-quarter reacted only to a supplemental allergen/substance. Screening series include common, important allergens, but these findings suggest that the addition of specialty allergens and personal or work products is critical for the successful diagnosis and management of allergic contact dermatitis.
引用
- Warshaw EM, Buonomo M, DeKoven JG, et al. Importance of Supplemental Patch Testing Beyond a Screening Series for Patients With Dermatitis: The North American Contact Dermatitis Group Experience. JAMA Dermatol. 2021. PMID: 34730775. doi:10.1001/jamadermatol.2021.4314
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。